Tomasz Szczepanski
Medical University of Silesia in Katowice, Poland
 


Affiliation:
Department of Pediatric Hematology and Oncology, Zabrze
Medical University of Silesia, Katowice, Poland.

Short bio:
Prof. Tomasz Szczepański completed his medical studies at the Silesian Academy of Medicine in Katowice in June 1994. After the studies and one year of internships in general medicine he received Rotary International Academic-Year Ambassadorial Scholarship for research training at department of Immunology, Erasmus MC, University Medical Center Rotterdam, The Netherlands. He continued the work in Rotterdam for the period 1997-1999 and on 13th November 2002 he defended cum laude the Ph.D. thesis entitled “Detection of minimal residual disease in acute lymphoblastic leukemia”. Since 2000 Tomasz Szczepański works at Department of Pediatric Hematology and Oncology in Zabrze of Medical University of Silesia in Katowice, Poland, where he obtained Specialist Certificates in Pediatrics (2005) and Pediatric Oncology and Hematology (2006).  After successful defense of Habilitation thesis entitled “Immunoglobulin and T-cell receptor gene rearrangements in B-cell-precursor acute lymphoblastic leukemia in childhood” (2005), Tomasz Szczepański has become an Independent Scientist at Medical University of Silesia in Katowice, Poland and since 2009 the Head of the Department of Pediatric Hematology and Oncology in Zabrze. After receiving professorship from the President of Poland he become a full professor at Medical University of Silesia. Currently, Prof. Szczepański also serves at the Medical University of Silesia as Rector Magnificus. He is a member of the Board of the Polish Pediatric Association and the President of the Polish Society of Pediatric Oncology and Hematology. He is co-author of > 300 publications, including > 150 international SCI publications. His works were cited > 6000 times, which resulted in Hirsch index of 41.

Selected publications:
  
  • Szczepański T, van der Velden VHJ, Waanders E, Kuiper RP, Van Vlierberghe P, Gruhn B, Eckert C, Panzer-Grümayer R, Basso G, Cavé H, zur Stadt U, Campana D, Schrauder A, Sutton R, van Wering E, Meijerink JPP, van Dongen JJM: Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol 2011; 29: 1643-1649.
  • Van Dongen JJM, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lécrevisse Q, Lucio P, Mejstrikova E, Szczepański T, Kalina T, de Tute R, Brüggemann M, Sedek L, Cullen M, Langerak AW, Mendonça A, Macintyre E, Martin-Ayuso M, Hrusak O, Vidriales MB, Orfao A: EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-1975.
  • Sędek L, Bulsa J, Sonsala A, Twardoch M, Wieczorek M, Malinowska I, Derwich K, Niedźwiecki M, Sobol-Milejska G, Kowalczyk JR, Mazur B, Szczepański T: The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: How different are they from their normal counterparts? Cytometry B Clin Cytom 2014; 18: 48-53.
  • Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, Sobral da Costa E, Kotrova M, Novakova M, Sonneveld E, Buracchi C, Bonaccorso P, Oliviera E, Te Marvelde JG, Szczepanski T, Lhermitte L, Hrusak O, Lecrevisse Q, Grigore GE, Fronkova E, Trka J, Brüggemann M, Orfao A, van Dongen JJ, van der Velden VH. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 2017, 129: 347-357.
  • Sędek Ł, Theunissen P, da Costa ES, van der Sluijs-Gelling A, Mejstrikova E, Gaipa G, Sonsala A, Twardoch M, Oliveira E, Novakova M, Buracchi C, van Dongen JJM, Orfao A, van der Velden VHJ, Szczepański T; EuroFlow Consortium: Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia. J Immunol Methods. 2019; 475: 112429.